ECRD 2012 Brussels 23-25 May: Still time to register!
The three-day conference will be held at the Management Centre Europe (MCE) Conference Centre in Brussels, Belgium from 23 - 25 May 2012. Interpretation will be provided in English, French, German, Spanish, Dutch and Russian for the plenary and other selected sessions. This is a unique opportunity (and tremendously expensive): take advantage of it!
ECRD 2012 is conceived as a European and international rare disease agora with a great deal of opportunity for networking, learning from each other, mixing all stakeholders, dedicated poster sessions and oral presentations of posters, tutorials for industry and academia, capacity building workshops for patient advocates and academic satellite meetings.
More than 130 posters, presented by theme, selected from more than 200 poster submissions, will be displayed in the main hall. In addition, for the first time at the ECRD, a series of 20 posters have been selected for oral presentations.
Combining public health, research and orphan products
The scope of the conference covers research, public health of rare diseases, all facets of orphan drugs and patient empowerment. “ECRD has a richer format, broader scope and brings new partnerships,” comments EURORDIS Chief Executive Officer, Yann Le Cam. “This year’s conference will bring together Rare Diseases and Orphan Product policies covering therapy development, and regulatory aspects, as well as issues and innovative solutions to improve access to Orphan Drugs.”
This revised format is brought to you thanks to a new partnership between EURORDIS and NORD with the Drug Information Association (DIA) with the objective of synchronizing efforts on both sides of the Atlantic in order to collect, educate, advocate and share experiences. The European Conference takes place in May and the US Conference takes place in October, every year.
To develop a robust programme, EURORDIS is partnering with the EU Committee of Experts on Rare Diseases (EUCERD), the European Medicines Agency (EMA) and particularly the EMA Committee on Orphan Medicinal Products (COMP), ORPHANET, the European Society of Human Genetics (ESHG), industry represented by EBE/EFPIA-EuropaBio, and the US National Organisation for Rare Diseases (NORD).
ECRD 2012 Brussels is not only a conference
The following important satellite meetings are organised at the same venue the day before, 23 May:
- Tutorials on Orphan Drug Development, Orphan Drug Designation and Marketing Authorisation, Registries and Health Technology Assessment for Rare Diseases. This is a new feature of ECRD thanks to DIA. Tutorials are training sessions intended for professionals working in industry or in academic research teams, that are also open to patient representatives.
- An Investors’ forum bringing together private investors and pharmaceutical and biotech companies, under the auspices of the EURORDIS Round Table of Companies (ERTC) and NORD Corporate Council. This is a new feature of ECRD to promote networking and investment in Europe for the development of rare disease therapies.
- The EURORDIS Membership Meeting with seven capacity building workshops and six forums to promote exchange of experience between patient advocates. The workshops will focus on building blocks for national plans. The forums will enable quick learning from each other in advocacy, communication and fund raising (Read article from March 2012 EURORDIS Newsletter).
The preliminary programme, registration and full conference details are available in English, French, Spanish, German, Dutch and Russian at www.rare-diseases.eu.
Don’t miss the most important date in the rare disease calendar!
This article was first published in the April 2012 issue of the EURORDIS newsletter
Author: Paloma Tejada
Photo credits: © EURORDIS
Page created: 17/03/2012
Page last updated: 02/04/2012